Loading clinical trials...
Loading clinical trials...
Elucidation of Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide (PTCy) as a Strategy for Graft Versus Host Disease Prevention in Haploidentical, Matched Related Donor and Matched Unrelated Donor Peripheral Blood Hematopoietic Cell Transplantation
Conditions
Interventions
Cyclophosphamide
Specimen collection
Locations
1
United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Start Date
July 13, 2018
Primary Completion Date
October 1, 2033
Completion Date
August 1, 2035
Last Updated
January 8, 2026
NCT03801434
NCT02560883
Lead Sponsor
Wake Forest University Health Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions